Ignite Creation Date:
2024-05-06 @ 10:43 AM
Last Modification Date:
2024-10-26 @ 12:34 PM
Study NCT ID:
NCT03333694
Status:
TERMINATED
Last Update Posted:
2020-12-11
First Post:
2017-10-12
Brief Title:
Safety Tolerability and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ SCCis
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Cutaneous Squamous Cell Carcinoma in Situ CSCCis |
Keywords:
| Name | View |
|---|---|
| Cutaneous Squamous Cell Carcinoma cSCC in situ mTOR kinase inhibitors PI3K inhibitor | View |